Have a question or topic idea for The Life Science Report? Submit it here.
Key Considerations for a US IPO Process
A DNB//Back Bay Healthcare Capital Markets Episode
Guests: Marc Recht (Cooley) and Kristoffer Braaten (DNB)
Length: 35 minutes
Air Date: May 21, 2024
In this DNB//Back Bay Healthcare Capital Markets Episode Vasilios Kofitsas who is a Partner and Managing Director at Back Bay Life Science Advisors speaks with Marc Recht who is a Partner and Co-Chair of the Global Life Sciences practice at Cooley and Kristoffer Braaten who is the Director and Head of Equity Capital Markets at DNB. They talk through the key considerations, mechanics and timelines of going public on a US exchange.
Cooley is among the top law firms for healthcare, tech and life science IPOs on both the issuer-side and underwriter-side. Their team of 1,300 lawyers is spread across 19 offices worldwide. DNB is an investment bank that works with supporting the healthcare industry, particularly in Europe and the US. DNB has offices in Oslo, Stockholm, Copenhagen, London, Singapore and New York.
Topics in this podcast include:
An overview of the decision-making process through execution for US-based and ex-US healthcare companies thinking about listing in the US
Core considerations after deciding to pursue a US listing and how to prepare most effectively
Building the “IPO advisory team”: types of advisors (legal, accounting, banking, IR firms, IP, etc.) and when to bring them in
Key documents and associated timelines related to the SEC documentation as well as investor outreach
What are the “don’ts” or mistakes companies make and how to avoid them
You can listen to previous episodes here or submit your inquiries here.
Learn more about the DNB//Back Bay Partnership and read our disclaimers at https://www.bblsa.com/dnb-back-bay-partnership.
Subscribe:
Apple Podcasts | Libsyn | Spotify | Stitcher